GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Revenio Group Oyj (OTCPK:REVXF) » Definitions » Cash Conversion Cycle

Revenio Group Oyj (Revenio Group Oyj) Cash Conversion Cycle : 51.86 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Revenio Group Oyj Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Revenio Group Oyj's Days Sales Outstanding for the three months ended in Mar. 2024 was 49.94.
Revenio Group Oyj's Days Inventory for the three months ended in Mar. 2024 was 139.56.
Revenio Group Oyj's Days Payable for the three months ended in Mar. 2024 was 137.64.
Therefore, Revenio Group Oyj's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 51.86.


Revenio Group Oyj Cash Conversion Cycle Historical Data

The historical data trend for Revenio Group Oyj's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revenio Group Oyj Cash Conversion Cycle Chart

Revenio Group Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.78 26.33 34.69 21.56 54.22

Revenio Group Oyj Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.85 -89.48 10.70 39.47 51.86

Competitive Comparison of Revenio Group Oyj's Cash Conversion Cycle

For the Medical Devices subindustry, Revenio Group Oyj's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revenio Group Oyj's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Revenio Group Oyj's Cash Conversion Cycle falls into.



Revenio Group Oyj Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Revenio Group Oyj's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=37.79+109.64-93.21
=54.22

Revenio Group Oyj's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=49.94+139.56-137.64
=51.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj  (OTCPK:REVXF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Revenio Group Oyj Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Revenio Group Oyj's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Revenio Group Oyj (Revenio Group Oyj) Business Description

Traded in Other Exchanges
Address
Ayritie 22, Vantaa, FIN, 01510
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, Other Europe, and Others.

Revenio Group Oyj (Revenio Group Oyj) Headlines

From GuruFocus

Q4 2023 Revenio Group Oyj Earnings Call Transcript

By GuruFocus Research 02-28-2024